Enquiry/Quote

How to Source Cotrimoxazole 800mg tablets for Pharmaceutical Formulation

Cotrimoxazole 800mg tablets (Tablets, 80 mg trimethoprim / 400 mg sulfamethoxazole) is classified under Transplant. It is therapeutically aligned with reference brands such as Bactrim, Septra(US & EU). This guide highlights key sourcing factors buyers should consider when procuring high-quality Cotrimoxazole 800mg tablets for formulation, R&D, or bulk manufacturing.

Product Overview: Cotrimoxazole tablets combine trimethoprim and sulfamethoxazole to inhibit bacterial folic acid synthesis, preventing DNA replication. It effectively treats urinary, respiratory, and skin infections. Benefits include broad-spectrum antibacterial activity, symptom relief, decreased infection transmission, and support for effectively managing urinary, respiratory, and skin bacterial infections. Cotrimoxazole tablets, marketed as Bactrim and Septra, are approved in the US by the FDA and in the...

Cotrimoxazole 800mg tablets API in Tablets form, 80 mg trimethoprim / 400 mg sulfamethoxazole specification
Cotrimoxazole 800mg tablets API – ideal for compliant pharmaceutical formulation.
Quick Insight: Over 60% of formulation delays are linked to poor API sourcing. A well-planned sourcing strategy can reduce risk and accelerate market entry.

1. Regulatory Compliance & Documentation

Ensure suppliers provide:

2. Purity, Grade & Specification Matching

Cotrimoxazole 800mg tablets must meet exact grade and purity for your dosage form:

3. Supplier Reliability & Audit History

4. Commercial Terms: Pricing, MOQ & Flexibility

5. Lead Time, Inventory & Logistics

Typical lead time for Cotrimoxazole 800mg tablets is 4–6 weeks.

6. Formulation Support

Pro Tip: Engage supplier formulation experts early — it can improve bioavailability and cut development time.

Conclusion

Sourcing Cotrimoxazole 800mg tablets is more than procurement—it’s a strategic partnership. With its tablets form and 80 mg trimethoprim / 400 mg sulfamethoxazole specification, choosing a compliant supplier ensures consistent quality and regulatory approval. Prioritize documentation, verify compatibility, and build relationships with transparent, reliable suppliers to secure long-term success.

Next Step: Get expert assistance in sourcing Cotrimoxazole 800mg tablets.

Request a Quote

Frequently Asked Questions For Sourcing of Cotrimoxazole 800mg tablets

What is the typical lead time for Cotrimoxazole 800mg tablets?

Lead times range from 4–6 weeks depending on supplier and region.

Is Cotrimoxazole 800mg tablets available in multiple grades?

Yes — common grades include USP, EP, and JP. Verify grade suitability for your dosage form before purchase.

Does Cotrimoxazole 800mg tablets require special storage?

It should be stored in a cool, dry place away from direct sunlight.

Is a Drug Master File (DMF) available for Cotrimoxazole 800mg tablets?

Yes, a DMF is available for regulated markets upon request. It includes detailed quality, manufacturing, and stability data.

Can I request samples or a pilot batch of Cotrimoxazole 800mg tablets?

Yes — pilot batches or samples can be arranged for R&D, stability studies, or formulation trials. MOQ may vary based on region and regulatory scope.

What compliance certificates are available for Cotrimoxazole 800mg tablets?

Available documentation may include GMP, ISO 9001, ISO 14001, and ICH Q7 certificates, along with CoA, TDS, and stability data.

Is Cotrimoxazole 800mg tablets suitable for regulated markets like US/EU?

Yes — compliant with EU/US/WHO GMP standards and available with regulatory support documentation for filings.

Can Cotrimoxazole 800mg tablets be used in fixed-dose combinations?

Yes — many formulations support inclusion in FDCs. Compatibility studies and formulation consultation are available on request.

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.